Home » Advanced Oncotherapy (AVO) » Advanced Oncotherapy – CEO, CFO & Non-Exec director purchase shares in the company

Advanced Oncotherapy – CEO, CFO & Non-Exec director purchase shares in the company

AVO1Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Sanjeev Pandya, Chief Executive Officer, and Nicolas Serandour, Chief Financial Officer, informed the Company on 5 June 2015 that they individually purchased 220,000 ordinary shares of 1 penny each in the Company at 9 pence per Ordinary Share on that day.

In addition, the Company was informed on 5 June 2015 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, purchased 1,500,000 Ordinary Shares at 9.81 pence per Ordinary Share on 3 June 2015.

Following these transactions Sanjeev Pandya now holds 590,400 Ordinary Shares representing 0.044% of the issued share capital of the Company, Nicolas Serandour now holds 220,000 Ordinary Shares representing 0.016%. Michael Bradfield now has a total beneficial interest in 122,018,510 Ordinary Shares representing 8.941%.

Advanced Oncotherapy Plc


Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Saif Janjua / Jon Levinson

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.